Florida is currently home to 3833 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC
Recruiting
The purpose of the study is to evaluate the feasibility, safety and tolerability of intravesical adoptive cell therapy using TIL (tumor infiltrating lymphocytes) in participants with urothelial cell carcinoma (UCC) non-muscle invasive bladder cancer (NMIBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Recruiting
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Sylvester Comprehensive Cancer Center, Miami, Florida
Conditions: Locally Advanced Solid Tumor
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
Recruiting
To determine the effect of a special preparation of cells, called tumor-infiltrating lymphocytes (TIL) stimulated with CD40L, when given with the drug nivolumab, for patients with EGFR, ALK, ROS1, or HER2-genomically altered lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)
Recruiting
Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a... Read More
Gender:
ALL
Ages:
Between 0 years and 25 years
Trial Updated:
05/05/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Severe Aplastic Anemia
Study of Canakinumab in Patients With Myelofibrosis
Recruiting
This is an open label, multicenter, phase 2 trial of Canakinumab in patients with primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF). Eligible patients will receive Canakinumab administered as a subcutaneous injection on day 1 of a 21 day cycle for a core study period of 8 cycles. Canakinumab will be given by subcutaneous injection (SC) injection at a starting dose of 200 mg (one 150 mg/mL syringe and one 50 mg/0.5 mL syringe) every 3 weeks.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, ET-MF, Post-polycythemia Vera Related Myelofibrosis, PV-MF
Habitat Escalated Adaptive Therapy (HEAT), With Neoadjuvant Radiation for Soft Tissue Sarcoma
Recruiting
The purpose of the study is to utilize radiomic images to precisely locate areas of tumor that can be treated with dose escalation radiation therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: High Grade Sarcoma
HEAL-IST IDE Trial
Recruiting
Inappropriate Sinus Tachycardia (IST) is a prevalent and debilitating condition in otherwise healthy younger patients, resulting in significant loss of quality of life, lacking effective treatment options or systematic clinical evidence to support a therapy. The primary objective of this clinical trial is to evaluate the safety and effectiveness of a hybrid sinus node sparing ablation procedure for the treatment of symptomatic drug refractory or drug intolerant IST.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/05/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Inappropriate Sinus Tachycardia
Diabetes RElated to Acute Pancreatitis and Its Mechanisms
Recruiting
The overriding objective of DREAM is to conduct a prospective longitudinal (36 months) observational clinical study to investigate the incidence, etiology, and pathophysiology of diabetes mellitus (DM) following acute pancreatitis (AP).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/05/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Acute Pancreatitis
Stellate Ganglion Block for PTSD
Recruiting
Posttraumatic Stress Disorder (PTSD) is a debilitating condition that affects about 15% of Veterans. Current treatments for Veterans with PTSD include medications and psychological therapies that help to process and desensitize to traumatic events. While effective for many, these treatments do not work for all patients, and many may refuse them. Stellate Ganglion Block (SGB), established to treat pain and other conditions, has shown promise for PTSD: early small studies show it may work fast and... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/05/2025
Locations: James A. Haley Veterans' Hospital, Tampa, FL, Tampa, Florida
Conditions: Post-traumatic Stress Disorder
Effectiveness and Safety of Embosphere Microspheres for Embolization of the Geniculate Artery for the Treatment of Pain With Known Moderate to Severe Knee Osteoarthritis
Recruiting
The purpose of this research study is to evaluate the effectiveness and safety of a permanent embolic (Embosphere Microspheres) for embolization of the geniculate artery for the treatment of moderate to severe knee osteoarthritis.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
05/05/2025
Locations: University of Miami, Miami, Florida
Conditions: Knee Osteoarthritis
Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
Recruiting
Hemophilia A (HA) is a genetic bleeding disorder resulting from a deficiency or absence of factor VIII (FVIII), which is necessary in the clotting process. This disorder occurs mostly in males and in severe cases causes frequent bleeding episodes in joints and muscles which can lead to progressive damage that affects mobility and quality of life. Prophylactic FVIII administered intravenously every other day has been the standard of care treatment for HA for the past few decades. Sports and phys... Read More
Gender:
MALE
Ages:
Between 6 years and 19 years
Trial Updated:
05/05/2025
Locations: Johns Hopkins All Children's Hospital, Saint Petersburg, Florida
Conditions: Hemophilia A
Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
Recruiting
Study J3Z-MC-OJAA is a Phase 1/2a, multicenter, open-label, ascending dose, first in-human study that will evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe Parkinson's disease with at least 1 pathogenic GBA1 mutation. Two dose level cohorts of LY3884961 are planned (Dose Level 1 and Dose Level 2). The duration of the study is 5 years. During the first year, patients will be evaluated for the effect of LY3884961 on safety, tolerability, immunogeni... Read More
Gender:
ALL
Ages:
Between 35 years and 80 years
Trial Updated:
05/05/2025
Locations: K2 Medical Research, 101 Southhall Lane, Suite 150, Maitland, Florida
Conditions: Parkinson Disease